Association between vitamins and risk of brain tumors: A systematic review and dose-response meta-analysis of observational studies

Weichunbai Zhang¹, Jing Jiang¹, Yongqi He¹, Xinyi Li², Shuo Yin¹, Feng Chen¹ and Wenbin Li¹,*

¹Department of Neuro-Oncology, Cancer Center, Beijing Tiantan Hospital, Capital Medical University, Beijing, China; ²College of Nursing, University of South Florida, Tampa, FL, United States

Background: Brain tumor is one of the important causes of cancer mortality, and the prognosis is poor. Therefore, early prevention of brain tumors is the key to reducing mortality due to brain tumors.

Objective: This review aims to quantitatively evaluate the association between vitamins and brain tumors by meta-analysis.

Methods: We searched articles on PubMed, Cochrane Library, Web of Science, and Embase databases from inception to 19 December 2021. According to heterogeneity, the fixed-effects model or random-effects model was selected to obtain the relative risk of the merger. Based on the methods described by Greenland and Longnecker, we explored the dose-response relationship between vitamins and the risk of brain tumors. Subgroup analysis, sensitivity analysis, and publication bias were also used for the analysis.

Results: The study reviewed 23 articles, including 1,347,426 controls and 6,449 brain tumor patients. This study included vitamin intake and circulating concentration. For intake, it mainly included vitamin A, vitamin B, vitamin C, vitamin E, β-carotene, and folate. For circulating concentrations, it mainly included vitamin E and vitamin D in the serum (25-hydroxyvitamin D and α-tocopherol). For vitamin intake, compared with the lowest intakes, the highest intakes of vitamin C (RR = 0.81, 95%CI:0.66–0.99, I² = 54.7%, P_{heterogeneity} = 0.007), β-carotene (RR = 0.78, 95%CI:0.66–0.93, I² = 0, P_{heterogeneity} = 0.460), and folate (RR = 0.66, 95%CI:0.55–0.80, I² = 0, P_{heterogeneity} = 0.661) significantly reduced the risk of brain tumors. For serum vitamins, compared with the lowest concentrations, the highest concentrations of serum α-tocopherol (RR = 0.61, 95%CI:0.44–0.86, I² = 0, P_{heterogeneity} = 0.656) significantly reduced the risk of brain tumors. The results of the dose-response relationship showed that increasing the intake of 100 μg folate per day reduced the risk of brain tumors by 7% (P_{nonlinearity} = 0.534, RR = 0.93, 95%CI:0.90–0.96).
Introduction

Brain tumors are the primary central nervous system tumors, with an annual incidence rate of 22.6/1,00,000 (1). They are a significant cause of cancer incidence rate and mortality, especially in children, accounting for 30% of cancer deaths (2). Because the prognosis of brain tumors, especially glioma, is poor, early prevention and detection are the keys to reducing brain tumor mortality (3).

Although the etiology of brain tumors had been studied for decades, the risk factors accounting for a large proportion of cases had not been found. In recent years, people had often paid attention to the relationship between diet and brain tumors. Some studies found that a diet rich in antioxidants, such as vegetables and fruits, could prevent brain tumors. Experimental studies had shown that these dietary antioxidants, could significantly inhibit the growth of cancer cells, especially brain tumor cells (4–6). Vitamins had a similar effect. Some vitamins with antioxidant properties, such as vitamin C and vitamin E, could inhibit tumor growth by eliminating free radicals and inducing apoptosis (7–9). In addition, fat-soluble vitamins, such as vitamin A and vitamin D, also played a certain preventive role by regulating cell differentiation and inhibiting cancer cell proliferation (9, 10). However, the current epidemiological results on vitamins and brain tumors were inconsistent. Chen et al. analyzed the diet of 236 patients with brain tumors through a case-control study and found that the intake of vitamin A was negatively correlated with the risk of glioma (odds ratio (OR) = 0.50, 95% confidence interval (95%CI):0.30–0.80) (11). However, Gile et al. arrived at the opposite conclusion (OR = 1.64, 95% CI:1.13–2.37) (12). A meta-analysis of seven articles showed that the highest intake of vitamin A in the diet was significantly associated with a reduced risk of glioma (relative risk (RR) = 0.80, 95% CI = 0.62–0.98, \( P = 0.014, I^2 = 54.9\% \)) (13). Tedeschi Blok et al. also found that people with a higher intake of carotene, the precursor of vitamin A, had a lower risk of brain tumors (OR = 0.72, 95% CI:0.54–0.98) (14), and vitamin C and vitamin E also had similar results in this study. However, Durrow et al. followed up with 545,770 participants for 7.2 years and found that dietary vitamin C (RR = 1.26, 95% CI: 0.96–1.66) and vitamin E (RR = 1.17, 95% CI:0.90–1.53) were not associated with the risk of brain tumors (15). Moreover, by detecting the concentrations of vitamin C and vitamin E in participants’ serum, it was found that both had protective effects on brain tumors (vitamin C: OR = 0.19, 95% CI: 0.10–0.60, vitamin E: RR = 0.65, 95% CI:0.44–0.96) (16). In addition, the effect of folate on brain tumors had also attracted much attention. Studies had shown that both folate supplementation during pregnancy and children’s high intake of folate could significantly reduce the risk of brain tumors (pregnant women OR = 0.60, 95% CI: 0.68–0.98, children: OR = 0.63, 95% CI: 0.41–0.97) (17).

Since the conclusions of previous studies were inconsistent, and most studies on the effects of vitamins on brain tumors included fewer cases, we quantitatively evaluated the relationship between various vitamin intake and in vivo exposure concentrations and brain tumor risk through the latest evidence of comprehensive observational studies. We tried to explore the dose-response relationship between vitamins and brain tumors, hoping to provide evidence for preventing brain tumors.

Methods

Search strategy

A comprehensive search was conducted for available articles published in English using databases such as the Cochrane Library, PubMed, Web of Science, and Embase up to 19 December 2021. The Cochrane Library search terms used for the title, abstract, and keywords were (“glioma” OR “brain cancer” OR “brain tumor”) combined with (“diet” OR “food” OR “lifestyle” OR “nutrition” OR “nutrient” OR “vitamin” OR “carotenoid” OR “carotene” OR “ascorbic acid” OR “thiamine” OR “riboflavine” OR “tocopherol” OR “25 hydroxyvitamin D” OR “folic acid” OR “nicotinic acid” OR “antioxidant”). The same retrieval strategy was also applied to the other databases. No document type or other relevant restrictions were used in the retrieval process, and unpublished articles were excluded. Two investigators independently searched articles and reviewed all retrieved studies. A third author settled any disagreements between the two authors. In addition, we explored the references of published meta-analyses to identify other potential articles.

Conclusion: Our analysis suggests that the intake of vitamin C, β-carotene, and folate can reduce the risk of brain tumors, while high serum α-tocopherol concentration also has a protective effect on brain tumors. Therefore, vitamins may provide new ideas for the prevention of brain tumors.

Systematic Review Registration: PROSPERO, identifier CRD420222300683.

KEYWORDS
vitamin, brain tumor, meta-analysis, β-carotene, folate, observational study
**Inclusion and exclusion criteria**

The following inclusion criteria were used: (1) the studies were using a cohort design or a case-control design; (2) the exposure of interest was vitamin intake or serum vitamin concentration; and (3) the ending outcome was brain tumors.

The exclusion criteria of the meta-analysis were as follows: (1) non-observational study (reviews, case reports, and clinical trials); (2) lack of effect size and 95%CI which were available for the highest category of vitamin vs. lowest category of vitamin; and (3) If multiple studies used data from the same population, the study with the largest sample size was included in this meta-analysis.

**Data extraction**

Two investigators extracted the following information from the included study independently: the first author, year of publication, country, study population, study type, age, sex, sample size, number of cases, disease, vitamin source, vitamin type, vitamin level, effect size, and 95% CI extracted from the most adjusted model. If there was disagreement between the two authors about the appropriateness of the data, it was resolved by consensus with a third author.

**Quality assessment**

Two investigators evaluated each study and handed it over to a third party for adjudication in case of disagreement. Since the included articles were observational studies, the Newcastle-Ottawa scale (NOS) was used to evaluate the quality of the study and the possible risk of bias (18).

**Statistical analysis**

Stata 14.0 software was used for data analysis. We pooled effect size estimations by combining the multivariable-adjusted effect size and 95%CI of the highest compared with the lowest vitamins. $I^2$ statistics assessed heterogeneity between the studies. Suppose the heterogeneity was not statistically significant ($I^2 < 50\%$ and $P > 0.10$), the fixed-effects model was used to pool them. Otherwise, the random-effects model was used. We conducted a subgroup analysis to determine whether the heterogeneity of the study came from disease (brain tumor and glioma), vitamin source (diet and supplements), study population (pregnancy exposure and self-exposure), study type (case-control study and cohort study), and study quality (>7 points and ≤7 points), to explore the potential sources of heterogeneity. We used sensitivity analysis to assess each study’s relative impact on the total effect size by successively omitting one study when determining the effect size. For publication bias, Egger’s test and Begg’s test were used to detect it.

Subsequently, we also explored the dose-response relationship between vitamins and brain tumor risk. The method developed by Greenland and Longnecker was used to analyze the dose-response relationship in this study (19). For this method, we needed to extract at least three groups of vitamin intakes or serum vitamin concentration, number of participants, number of cases, effect size, and 95% CI in each study. The median or average vitamin corresponding to each group was used for risk estimation for each study. Suppose the median or average vitamin of each group was not provided, the midpoint of each group’s upper and lower limits should be designated as the intermediate exposure level. If the highest group was open, we assumed that the interval width was the same as the second-highest category. Q-value was applied to assess between-study heterogeneity. Unless otherwise noted, two-tailed $P < 0.05$ was accepted as statistically significant.

**Results**

**Study characteristics**

Figure 1 shows the articles screening process of this study. A total of 3,604 articles were retrieved, including 387 from the Cochrane Library, 896 from PubMed, 307 from Web of Science, and 2014 from Embase. After excluding duplicates between different databases, titles and abstracts of 2,493 articles were reviewed. A total of 2,340 articles were excluded because they were not related to the aim of the study. Then, 153 articles were reviewed in full text, and 130 articles were excluded due to non-observational studies, animal/cell experiments, reviews, lacked effect size, or duplication of the study population. A total of 23 articles were included (11, 12, 14–17, 20–36).

Table 1 summarizes the 23 articles and characteristics included in this meta-analysis. All studies included 1,347,426 controls and 6,449 patients with brain tumors. Among them, the patients in eight studies were minors, and the participants in the other studies were 18–80 years old. The included studies were mainly concentrated in North America (America and Canada) and Europe (Britain, Germany, and Sweden). A few studies were completed by Australia, China, and Iran, including 20 case-control studies and 4 cohort studies. These studies provided brain tumor-related results for 6 vitamin intakes: vitamin A, vitamin B, vitamin C, vitamin E, β-carotene, and folate. In addition, there were the results of serum 25-hydroxyvitamin D and serum α-tocopherol. Around 50% of the studies had a NOS score of eight or above.
FIGURE 1
Flow diagram outlining the systematic search and articles selection process.
| Study                  | Year | Country  | Study type | Age | Sex | Population | Sample size | Case | Disease | Source | Vitamin       | Effect size (95%CI) | Quality score |
|------------------------|------|----------|------------|-----|-----|------------|-------------|------|---------|--------|---------------|------------------|--------------|
| Howe et al. (20)       | 1989 | Canada   | Case-control | <19 | Both | Self-exposure | 146          | 52   | Brain tumor | Supplement | Vitamin C 0.91(0.43–1.93) | 8              |
| Boeing et al. (21)     | 1993 | Germany  | Case-control | 25–75 | Both | Self-exposure | 470          | 93   | Glioma     | Diet     | Vitamin C 0.90(0.50–1.70) | 7              |
| Bunin et al. (22)      | 1994 | America  | Case-control | 0–6  | Female | Pregnancy exposure | 288          | 144  | Glioma     | Diet     | Vitamin A 0.70(0.30–1.40) | 8              |
| Gile et al. (12)       | 1994 | Australia | Case-control | 20–70 | Both | Self-exposure | 818          | 409  | Glioma     | Diet     | Vitamin A 1.64(1.3–2.37) | 7              |
| Blowers et al. (23)    | 1997 | America  | Case-control | 25–74 | Female | Self-exposure | 188          | 94   | Glioma     | Diet     | Vitamin C 0.70(0.30–1.90) | 7              |
| Lee et al. (24)        | 1997 | America  | Case-control | >20  | Both | Self-exposure | 857          | 419  | Glioma     | Supplement | Vitamin C 1.50(0.60–4.10) | 7              |
| Preston-Martin et al. (25) | 1998 | Britain | Case-control | 0–19 | Female | Pregnancy exposure | 952          | 373  | Brain tumor | Supplement | Vitamin C 0.40(0.20–0.80) | 7              |
| Hu et al. (26)         | 1999 | China    | Case-control | 20–74 | Both | Self-exposure | 287          | 129  | Brain tumor | Diet     | Vitamin C 0.50(0.30–0.80) | 6              |
| Schwartzbahm et al. (16) | 2000 | America  | Case-control | 36–69 | Both | Self-exposure | 69           | 34   | Glioma     | Serum    | Vitamin C 0.36(10.10–1.10) | 8              |
| Chen et al. (11)       | 2002 | America  | Case-control | ≥21  | Both | Self-exposure | 685          | 236  | Glioma     | Diet     | Vitamin A 0.50(0.30–0.80) | 7              |
| Tedeschi-Blok et al. (14) | 2006 | America  | Case-control | ≥20  | Both | Self-exposure | 1,648        | 802  | Glioma     | Diet     | Vitamin C 0.70(0.51–0.94) | 9              |

(Continued)
| Study               | Year | Country | Study type | Age  | Sex\(^a\) | Population\(^b\) | Sample size | Case   | Disease | Source | Vitamin             | Effect size (95%CI) | Quality score |
|---------------------|------|---------|------------|------|-----------|-----------------|-------------|--------|---------|--------|---------------------|-------------------|---------------|
| Holick et al. (27)  | 2007 | America | Cohort     | 25–75| Both      | Self-exposure   | 2,29,637    | 296    | Glioma  | Diet    | β-carotene          | 0.92(0.64–1.32)  | 8             |
| Michaud et al. (28) | 2009 | America | Cohort     | 25–75| Both      | Self-exposure   | 2,13,334    | 335    | Glioma  | Diet    | Vitamin C           | 0.88(0.62–1.26)  | 8             |
|                     |      |         |            |      |           |                 |             |        |         |        | Vitamin E           | 0.98(0.67–1.43)  |               |
| Dubrow et al. (15)  | 2010 | America | Cohort     | 50–71| Both      | Self-exposure   | 5,45,770    | 585    | Glioma  | Diet    | Vitamin C           | 1.26(0.96–1.66)  | 7             |
|                     |      |         |            |      |           |                 |             |        |         |        | Vitamin E           | 1.17(0.90–1.53)  |               |
| Stalberg et al. (29)| 2010 | Sweden  | Case-control| 0–15| Female   | Pregnancy exposure | 1,037  | 512    | Brain tumor | Supplement | Folate | 0.60(0.30–1.10)  |                     | 9             |
| Méline et al. (17)  | 2012 | Australia | Case-control | 0–14| Female   | Pregnancy exposure | 1,014  | 287    | Brain tumor | Supplement | Vitamin A | 1.17(0.72–1.90)  |                     | 8             |
|                     |      |         |            |      |           |                 |             |        |         |        | Vitamin B           | 1.03(0.68–1.56)  |               |
|                     |      |         |            |      |           |                 |             |        |         |        | Vitamin C           | 0.96(0.64–1.46)  |               |
|                     |      |         |            |      |           |                 |             |        |         |        | Folate              | 0.60(0.38–0.98)  |               |
|                     |      |         |            |      |           |                 |             |        |         |        | Vitamin B           | 1.04(0.72–1.50)  |               |
|                     |      |         |            |      |           |                 |             |        |         |        | Folate              | 0.70(0.48–1.02)  |               |
|                     |      |         |            |      |           |                 |             |        |         |        | Vitamin B           | 1.30(0.89–2.20)  |               |
|                     |      |         |            |      |           |                 |             |        |         |        | Vitamin B           | 0.63(0.41–0.97)  |               |
|                     |      |         |            |      |           |                 |             |        |         |        | Vitamin C           | 1.23(0.80–1.89)  |               |
|                     |      |         |            |      |           |                 |             |        |         |        | Folate              | 0.41(0.26–0.63)  |               |
|                     |      |         |            |      |           |                 |             |        |         |        | Vitamin B           | 1.04(0.73–1.47)  |               |
|                     |      |         |            |      |           |                 |             |        |         |        | Vitamin B           | 0.65(0.44–0.96)  |               |
|                     |      |         |            |      |           |                 |             |        |         |        | Vitamin C           | 0.35(0.13–0.97)  |               |
| Huang et al. (34)   | 2017 | America | Case-control| 50–69| Male     | Self-exposure   | 128         | 64     | Glioma  | Serum   | α-tocopherol        | 0.65(0.44–0.96)  | 8             |
| Heydari et al. (35) | 2020 | Iran    | Case-control| 20–75| Both     | Self-exposure   | 384         | 128    | Glioma  | Diet    | Vitamin B           | 0.49(0.51–0.96)  | 8             |
|                     |      |         |            |      |           |                 |             |        |         |        | Vitamin C           | 0.35(0.13–0.97)  |               |
|                     |      |         |            |      |           |                 |             |        |         |        | Vitamin E           | 0.83(0.35–1.97)  |               |
|                     |      |         |            |      |           |                 |             |        |         |        | β-carotene          | 0.99(0.45–2.18)  |               |
| Yue et al. (36)     | 2021 | America | Cohort     | 40–69| Both     | Self-exposure   | 3,46,812    | 444    | Glioma  | Serum   | 25-hydroxyvitamin D | 0.87(0.68–1.11)  | 8             |
| Yue et al. (36)     | 2021 | America | Case-control| 30–55| Both     | Self-exposure   | 252         | 84     | Glioma  | Serum   | 25-hydroxyvitamin D | 0.97(0.51–1.85)  | 8             |

\(^{a}\)Sex of exposed population.

\(^{b}\)The population was divided into pregnancy exposure and self-exposure.
TABLE 2 A meta-analysis of the association between vitamins and brain tumors.

| Vitamins                  | Number of studies | RR (95%CI)   | $I^2$ (%) | $P$ for heterogeneity |
|---------------------------|-------------------|--------------|-----------|-----------------------|
| **Intake**                |                   |              |           |                       |
| Vitamin A                 | 6                 | 0.79(0.48–1.29) | 77.9%     | <0.001                |
| Vitamin B                 | 4                 | 1.03(0.82–1.29) | 41.1%     | 0.165                 |
| Vitamin C                 | 14                | 0.81(0.66–0.99) | 54.7%     | 0.007                 |
| Vitamin E                 | 11                | 0.83(0.63–1.10) | 73.5%     | <0.001                |
| β-carotene                | 7                 | 0.78(0.66–0.93) | 0         | 0.460                 |
| Folate                    | 7                 | 0.66(0.55–0.80) | 0         | 0.661                 |
| **Serum**                 |                   |              |           |                       |
| Serum 25-hydroxyvitamin D | 4                 | 0.97(0.81–1.16) | 0         | 0.533                 |
| Serum α-tocopherol        | 3                 | 0.61(0.44–0.86) | 0         | 0.656                 |

Effect size estimations of risk for the association between vitamins and brain tumor

The effect size estimations between all vitamins and risk of brain tumors are shown in Table 2. For vitamin intake, compared with the lowest intakes, the highest intakes of vitamin C (RR = 0.79, 95%CI:0.66–0.99, $I^2 = 54.7\%$, $P_{\text{for heterogeneity}} = 0.007$), β-carotene (RR = 0.78, 95%CI:0.66–0.93, $I^2 = 0$, $P_{\text{for heterogeneity}} = 0.460$), and folate (RR = 0.66, 95%CI:0.55–0.80, $I^2 = 0$, $P_{\text{for heterogeneity}} = 0.661$) significantly reduced the risk of brain tumor, while the highest intakes of vitamin A (RR = 0.79, 95%CI:0.48–1.29, $I^2 = 77.9\%$, $P_{\text{for heterogeneity}} < 0.001$), vitamin B (RR = 1.03, 95%CI:0.82–1.29, $I^2 = 41.1\%$, $P_{\text{for heterogeneity}} = 0.165$), and vitamin E (RR = 0.83, 95%CI:0.63–1.10, $I^2 = 73.5\%$, $P_{\text{for heterogeneity}} < 0.001$) were not related to the incidence of brain tumor. For serum vitamin, compared with the lowest concentrations, the highest concentrations of serum α-tocopherol (RR = 0.61, 95%CI:0.44–0.86, $I^2 = 0$, $P_{\text{for heterogeneity}} = 0.656$), while the highest concentrations of serum 25-hydroxyvitamin D (RR = 0.97, 95%CI:0.81–1.16, $I^2 = 0$, $P_{\text{for heterogeneity}} = 0.533$) was not related to the incidence of brain tumor (Supplementary Figures 1–8).

Subgroup analysis

For disease, vitamin E was statistically significant in the brain tumor subgroup (RR = 0.30, 95%CI:0.10–0.90). For vitamin source, vitamin C was statistically significant in the supplement subgroup (RR = 0.77, 95%CI:0.60–0.98). For the study population, vitamin E was statistically significant in the pregnancy exposure subgroup (RR = 0.55, 95%CI:0.37–0.83). For the study area, vitamin A was statistically significant in the subgroups of America, Europe, and Australia (America: RR = 0.57, 95%CI:0.39–0.84; Europe: RR = 0.40, 95%CI:0.20–0.80; and Australia: RR = 1.44, 95%CI:1.04–1.99), and the heterogeneity of vitamin A decreased from 77.9 to 15.0%. For study type, vitamin C was statistically significant in the case-control study subgroup (RR = 0.75, 95%CI:0.61–0.93) (Table 3).

For vitamin C, when Heydari's study (35) was excluded, the results of all studies and brain tumor risk remained significant, but the heterogeneity decreased significantly (RR = 0.87, 95%CI:0.77–0.99, $I^2 = 23.4\%$, $P_{\text{for heterogeneity}} = 0.207$). Similarly, excluding another study (26), the heterogeneity of vitamin E was also significantly reduced (RR = 0.94, 95%CI:0.76–1.16, $I^2 = 52.3\%$, $P_{\text{for heterogeneity}} = 0.026$). It was speculated that these studies might be the main reasons for the heterogeneity of vitamin C and brain tumor risk. The sources of heterogeneity between vitamin B intake and brain tumor effect size estimations were unclear.

The heterogeneity of β-carotene, folate, serum 25-hydroxyvitamin D, and serum α-tocopherol was minimal, so no subgroup analysis was carried out.

Sensitivity analysis and publication bias

The sensitivity analysis showed that no individual study had an excessive influence on the association of vitamins and brain tumors when we removed one individual study at a time. This suggested the results of this meta-analysis were relatively stable (Table 4).

Publication bias was evaluated by Egger's regression test and Begg's rank correlation method. The $P$-value of publication bias of vitamins was more significant than 0.1, suggesting that the difference was not statistically significant, thus there was no publication bias (Table 4).

Dose-response relationship

Due to the limited number of available articles, only vitamin C, vitamin E, folate, and serum 25-hydroxyvitamin D could...
### TABLE 3 Subgroup analysis for the association between vitamins and brain tumors.

| Vitamin  | Subgroup       | Number | RR (95%CI)     | $I^2$ (%) | $P_{\text{for heterogeneity}}$ |
|----------|----------------|--------|----------------|-----------|---------------------------------|
| Vitamin A| Disease        |        |                |           |                                 |
|          | Glioma         | 4      | 0.82 (0.42-1.61) | 81.1      | 0.001                           |
|          | Brain tumor    | 2      | 0.70 (0.25-2.01) | 83.8      | 0.013                           |
| Vitamin source |        |        |                |           |                                 |
| Diet     |                | 4      | 0.82 (0.42-1.61) | 81.1      | 0.001                           |
| Supplement |            | 2      | 0.70 (0.25-2.01) | 83.8      | 0.013                           |
| Study population |      |        |                |           |                                 |
| Pregnancy exposure | | 3      | 0.71 (0.37-1.38) | 68.3      | 0.043                           |
| Self-exposure   |            | 3      | 0.85 (0.36-2.03) | 86.7      | 0.001                           |
| Study area    |                |        |                |           |                                 |
| America     |                | 3      | 0.57 (0.39-0.84) | 0         | 0.692                           |
| Europe      |                | 1      | 0.40 (0.20-0.80) | -         | -                               |
| Australia   |                | 2      | 1.44 (1.04-1.99) | 15.0      | 0.278                           |
| Study quality |          |        |                |           |                                 |
| ≤7         |                | 4      | 0.71 (0.33-1.52) | 85.8      | < 0.001                         |
| >7         |                | 2      | 0.99 (0.62-1.59) | 18.3      | 0.269                           |
| Vitamin B  | Study population |      |                |           |                                 |
| Pregnancy exposure | | 2      | 1.04 (0.79-1.36) | 0         | 0.973                           |
| Self-exposure |            | 2      | 1.01 (0.68-1.50) | 80.3      | 0.024                           |
| Study quality |          |        |                |           |                                 |
| ≤7         |                | 2      | 1.01 (0.68-1.50) | 80.3      | 0.024                           |
| >7         |                | 2      | 1.04 (0.79-1.36) | 0         | 0.973                           |
| Vitamin C  | Disease       |        |                |           |                                 |
| Glioma     |                | 10     | 0.82 (0.64-1.05) | 63.5      | 0.003                           |
| Brain tumor|                | 4      | 0.77 (0.54-1.09) | 17.9      | 0.301                           |
| Vitamin source |        |        |                |           |                                 |
| Diet       |                | 10     | 0.82 (0.62-1.09) | 62.1      | 0.005                           |
| Supplement |                | 4      | 0.77 (0.60-0.98) | 18.3      | 0.299                           |
| Study population |      |        |                |           |                                 |
| Pregnancy exposure | | 3      | 0.72 (0.48-1.08) | 43.0      | 0.173                           |
| Self-exposure |            | 11     | 0.84 (0.66-1.07) | 58.8      | 0.007                           |
| Study area  |                |        |                |           |                                 |
| America     |                | 8      | 0.89 (0.73-1.08) | 38.1      | 0.126                           |
| Europe      |                | 2      | 0.66 (0.37-1.17) | 49.1      | 0.161                           |
| Australia   |                | 2      | 0.96 (0.66-1.39) | 0         | 1.000                           |
| Asia        |                | 2      | 0.30 (0.06-1.59) | 71.3      | 0.062                           |
| Study type  |                |        |                |           |                                 |
| Case-control |            | 12     | 0.75 (0.61-0.93) | 39.5      | 0.077                           |
| Cohort      |                | 2      | 1.07 (0.76-1.52) | 59.4      | 0.116                           |
| Study quality |          |        |                |           |                                 |
| ≤7         |                | 8      | 0.77 (0.50-1.19) | 71.8      | 0.001                           |
| >7         |                | 6      | 0.79 (0.68-0.93) | 0         | 0.829                           |
| Vitamin E  | Disease       |        |                |           |                                 |
| Glioma     |                | 9      | 1.02 (0.85-1.21) | 28.0      | 0.195                           |
| Brain tumor|                | 2      | 0.30 (0.10-0.90) | 82.2      | 0.018                           |

(Continued)
TABLE 3 Continued

| Vitamin | Subgroup                  | Number | RR (95%CI)                | I² (%) | P for heterogeneity |
|---------|---------------------------|--------|---------------------------|--------|--------------------|
| Diet    |                           | 9      | 0.89 (0.65–1.23)          | 73.0   | <0.001             |
| Supplement |                       | 2      | 0.65 (0.42–1.01)          | 53.6   | 0.142              |
| Study population |               |        |                           |        |                    |
| Pregnancy exposure | 2 | 0.55 (0.37–0.83) | 0 | 0.455             |
| Self-exposure     | 9 | 0.90 (0.67–1.21) | 73.6 | <0.001             |
| Study area       |                           |        |                           |        |                    |
| America          | 7 | 0.97 (0.81–1.15) | 16.8 | 0.302              |
| Europe           | 1 | 0.50 (0.31–0.82) | -  | -                  |
| Australia        | 1 | 1.42 (1.00–2.02) | -  | -                  |
| Asia             | 2 | 0.36 (0.07–1.81) | 86.6 | 0.006              |
| Study type       |                           |        |                           |        |                    |
| Case-control     | 9 | 0.77 (0.53–1.10) | 76.1 | <0.001             |
| Cohort           | 2 | 1.10 (0.89–1.37) | 0 | 0.453              |
| Study quality    |                           |        |                           |        |                    |
| ≤7               | 7 | 0.80 (0.50–1.29) | 83.4 | <0.001             |
| >7               | 4 | 0.87 (0.71–1.07) | 0 | 0.792              |
| β-carotene       |                           |        |                           |        |                    |
| Study quality    |                           |        |                           |        |                    |
| ≤7               | 4 | 0.73 (0.55–0.97) | 23.2 | 0.272              |
| >7               | 3 | 0.81 (0.65–1.01) | 0 | 0.489              |
| Folate           |                           |        |                           |        |                    |
| Disease          |                           |        |                           |        |                    |
| Glioma           | 2 | 0.94 (0.60–1.45) | 0 | 0.819              |
| Brain tumor      | 5 | 0.62 (0.50–0.76) | 0 | 0.884              |
| Vitamin source   |                           |        |                           |        |                    |
| Diet             | 5 | 0.71 (0.57–0.88) | 0 | 0.667              |
| Supplement       | 2 | 0.53 (0.36–0.79) | 0 | 0.661              |
| Study population |                           |        |                           |        |                    |
| Pregnancy exposure | 5 | 0.64 (0.51–0.80) | 0 | 0.597              |
| Self-exposure    | 2 | 0.72 (0.51–1.01) | 0.3 | 0.317              |
| Study quality    |                           |        |                           |        |                    |
| ≤7               | 3 | 0.64 (0.48–0.85) | 18.6 | 0.293              |
| >7               | 4 | 0.68 (0.53–0.88) | 0 | 0.673              |

be analyzed for dose-response relationship from nine articles. The dose-response relationship between vitamins and the risk of brain tumor is shown in Figure 2. There was a significant linear dose-response relationship between folate and brain tumor, and increasing 100 µg folate per day reduced brain tumor risk by 7% (P_{nonlinearity} = 0.534, 95%CI:0.90–0.96). Although vitamin C, vitamin E, and serum 25-hydroxyvitamin D had similar linear trends, the results were insignificant due to insufficient studies.

**Discussion**

Based on 23 articles on vitamins and brain tumors published from 1989 to 2021, a total of 1,347,426 controls and 6,449 patients with brain tumors were included. Our meta-analysis results showed that for vitamin intake, higher intakes of vitamin C, β-carotene, and folate had a significant protective effect on brain tumors. For vitamin concentration *in vitro*, high serum α-tocopherol concentration could significantly reduce the risk of brain tumors. There was no significant correlation between vitamin A, vitamin B, vitamin E, and serum 25-hydroxyvitamin D and the incidence of brain tumors. There was a significant linear dose-response relationship between folate and brain tumor, and increasing per 100 µg/day folate intake reduced brain tumor risk by 7%. Although there were similar linear trends between vitamin C, vitamin E, serum 25-hydroxyvitamin D, and brain tumor risk, the results were insignificant. This might be due to the limited number of articles that analyzed the dose-response relationship between these vitamins and brain tumors.

We explored the sources of heterogeneity through disease conditions, vitamin sources, study population, study area, study
TABLE 4 Sensitivity analysis and publication bias.

| Vitamin         | Influential analysis | Egger's test | Begg's test |
|-----------------|----------------------|--------------|-------------|
| Vitamin A       | 0.38–1.48            | 0.169        | 0.707       |
| Vitamin B       | 0.74–1.37            | 0.101        | 0.734       |
| Vitamin C       | 0.63–1.03            | 0.296        | 0.743       |
| Vitamin E       | 0.58–1.17            | 0.170        | 0.276       |
| β-carotene      | 0.61–1.00            | 0.658        | 0.764       |
| Folate          | 0.52–0.85            | 0.462        | 0.764       |
| Serum 25-hydroxyvitamin D | 0.76–1.42 | 0.300        | 0.734       |
| Serum α-tocopherol | 0.28–1.00 | 0.302        | 0.296       |

FIGURE 2
Risk between vitamins and brain tumors estimates from dose-response meta-analysis.

Type, and study quality. The results of vitamin A were not significant, but through subgroup analysis, it was found that its heterogeneity mainly comes from the study area. The results of European and American studies showed that vitamin A had a protective effect on brain tumors. In contrast, the results of Australian studies suggested that excessive intake of vitamin A could significantly increase the risk of brain tumors. It was speculated that there was a significant difference in the intake of vitamin A due to different eating habits in the northern and southern hemispheres. Heydari’s study contributed the most heterogeneity to the meta-analysis of vitamin C and brain tumors (35). It is well-known that the primary dietary sources of vitamin C are vegetables and fruits. Heydari’s research showed that about 60% of Iranian adults had low fruit and vegetable intake, and the average intake of vitamin C in the control population was 143 mg/day (35), while half of the American people in Michaud et al.’s (28) study had more than 232 mg/day. Therefore, there were significant differences in vitamin C intake between the Iranian and other populations, resulting in considerable heterogeneity in this study. In addition, in the study of Hu et al. (26) only 57 kinds of food were investigated. In comparison, most of the food types investigated were more than 80 kinds in other studies, which might not obtain accurate vitamin intake, resulting in the heterogeneity of vitamin E.

Compared with other tissues, the brain has active metabolism and can produce many reactive oxygen species.
Still, the brain has low antioxidant defense ability, leading to DNA loss and tumor development (37). A case-control study of dietary antioxidants and glioma conducted by Tedeschi Blok et al. found that a higher intake of vitamin C was associated with a reduced risk of glioma (RR = 0.70, 95% CI:0.51–0.94) (14). Preston-martin et al. found that prenatal vitamin C supplementation could significantly reduce the risk of brain tumors in children (RR = 0.50, 95% CI:0.30–0.90). There was a dose-response relationship between intake and brain tumor risk (25). On the one hand, vitamin C could inhibit and reduce N-acetyltransferase activity and the formation of 2-aminofluorene-DNA adduct in rat C6 glioma cells in a dose-dependent manner (38). On the other hand, the rat experiment found that two markers related to brain tumor proliferation, platelet-derived growth factor receptor (PDGFRβ), were found in rats fed with antioxidants such as vitamin C. Furthermore, Ki-67 transcripts were significantly reduced, suggesting that vitamin C could limit the invasiveness of brain tumors (39). In addition, some studies had found that vitamin C could inhibit the growth of glioblastoma through the caspase-3 death pathway and then assist the treatment of glioblastoma with methotrexate (40). Although our results did not find the protective effect of vitamin E intake on brain tumors, which was consistent with the results of two cohort studies in the United States (15, 28), the survival rate of patients with high vitamin E intake was higher in patients with grade III malignant glioma (41). Moreover, vitamin E derivatives reduced the incidence of pituitary tumors in X-ray-irradiated mice (42). We could not rule out the individual metabolic differences of vitamin E, resulting in inconsistent results. The results of prospective glioma serum metabolomics showed that serum α-tocopherol (the most bioactive form of vitamin E) concentrations were significantly negatively correlated with glioma risk (34), which was consistent with the results of the meta-analysis of serum α-tocopherol. We found that vitamin A intake had no significant effect on brain tumors. At present, there was no cohort study to explore the association between vitamin A and brain tumors, and the conclusions of case-control studies were inconsistent. Still, the previous meta-analysis showed that vitamin A could reduce the risk of glioma (RR = 0.80, 95% CI = 0.62–0.98, I² = 54.9%) (13). There were few studies on the mechanism of vitamin A and brain tumors. Some studies believed that brain tumors were closely related to retinoic acid, the metabolite of vitamin A and the level of retinoic acid-binding protein 2 in brain tumors were low related to the survival rate of patients (43). Although the relationship between vitamin A and brain tumors was not clear, β-carotene, as a precursor of vitamin A, showed a protective effect on brain tumors. Tedeschi Blok et al. found that the average intake of β-carotene in the control population was 252.8 mg/day (RR = 0.72, 95% CI:0.54–0.98) higher than that in patients with brain tumors, and the serum β-carotene concentration in patients with brain tumors was also significantly lower than that in healthy people (44). Cell experiments confirmed that β-carotene could effectively inhibit DNA synthesis in growing C-6 glioma cells (45). In addition, in the study of vegetable intake and brain tumors, it was also found that compared with other vegetables, orange vegetables rich in β-carotene had a stronger protective effect on brain tumors (11, 46). This study was the first time that folate could reduce the risk of brain tumors in the meta-analysis, which was consistent with the results of many epidemiological studies (17, 32). In recent years, the effect of folate on brain tumors had attracted much attention, especially in children. It had been found that the deficiency of folate metabolism might play an important role in the pathogenesis of some specific subtypes of brain tumors in children, especially embryonic central nervous system tumors (47). The mechanism might be related to the folate receptor. On the one hand, the folate receptor was found to be overexpressed in ependymoma, medulloblastoma, and other common malignant tumors of children’s central nervous system (48, 49). Moreover, folate supplementation can enhance DNA remethylation through SP1/SP3 mediated transcriptional upregulation of DNMT3a and DNMT3b protein-coding genes to limit the invasiveness of glioma (50). In addition, targeted folate metabolism had selective cytotoxicity to glioma stem cells and can effectively cooperate with differentiation therapy to eliminate tumor-initiating cells in xenogeneic glioma grafts (51). However, only a few studies had reported the association between vitamin B and brain tumors, and the results were not significant. We also did not find any relevant research on dietary vitamin D and brain tumors. Since sunlight could promote vitamin D synthesis in vivo, it seemed more scientific to evaluate its effect on brain tumors through vitamin D concentration in vivo. Although experimental studies had shown that Vitamin D could promote cell cycle arrest and induce cell death to suppress tumor growth in glioblastoma (52, 53). However, no significant effect of vitamin D on brain tumors was found in epidemiological studies (31, 33).

So far, this was the largest meta-analysis of vitamins and brain tumors. Therefore, this study had several advantages. First, this study was the first meta-analysis involving the effects of multivitamins on brain tumors, including seven vitamins. The protective effects of β-carotene and folate on brain tumors were found in a meta-analysis for the first time. The dose-response relationship between folate and the risk of brain tumors was explored, which provided new evidence for preventing brain tumors. Second, this study also explored the relationship between vitamin concentration in serum and brain tumors to confirm the actual effect of vitamin intake. Third, we thoroughly discussed the sources of heterogeneity of the research results and improved the accuracy of the significant results. However, the study also had limitations. This study failed to further explore the relationship between vitamin and brain tumor subtypes. The incidence rate of brain tumors is very low, and the annual incidence rate was only 22.6/10 million (1). Although our current study included most observational studies of vitamins
and brain tumors, the sample size was still limited compared with other tumor studies. In addition, glioma is the most common brain tumor. Therefore, most of the current related studies focused on gliomas or brain tumors, especially in meta-analyses and systematic reviews (54, 55). In the search process, we did not find any studies that met the inclusion criteria, and the subjects had meningioma, germ cell tumor, or other brain tumor diseases. As a considerable part of the exposed population was pregnant women, and the outcomes of relevant studies were child brain tumors, this might cause some heterogeneity in the analysis process. However, we discussed the results of pregnancy exposure and self-exposure in the subgroup analysis and obtained similar results in some vitamins (such as folate). Most studies could only provide the source of intake of a particular vitamin (diet or supplement), so it was impossible to comprehensively evaluate the relationship between the overall intake of vitamins and brain tumors. Next, for the study of vitamin concentrations in vivo, only vitamin D and vitamin E provide sufficient articles, and there were too few studies on the concentrations of other vitamins to explore their correlation fully. We hope to improve the relevant analysis by adding more articles in future research.

Conclusion

In summary, the current meta-analysis shows that higher intakes of vitamin C, β-carotene, and folate can reduce the risk of brain tumors. At the same time, high serum α-tocopherol concentration also has a protective effect on brain tumors. Therefore, vitamins may provide new ideas for the prevention of brain tumors. In the future, we should pay attention to the compounds with antioxidant effects in the diet to further discover their effects on brain tumors.

Data availability statement

The original contributions presented in the study are included in the article/Supplementary material, further inquiries can be directed to the corresponding author/s.

Author contributions

WL and WZ contributed to the conception or design of the work, WZ, JJ, and YH contributed to searching the databases. WZ, JJ, and XL contributed to the acquisition, analysis, or interpretation of data for the work. WZ, XL, and SY proofread and modified the language. WL and FC reviewed and edited the manuscript. All authors have read and approved the final manuscript.

Funding

This study was supported by the National Natural Science Foundation of Beijing (No. J200003) and the National Science and Technology Major Project of China (No. 2016ZX09101017).

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fnut.2022.935706/full#supplementary-material

References

1. Barnholtz-Sloan JS, Ostrom QT, Cote D. Epidemiology of brain tumors. Neurol Clin. (2018) 36:395–419. doi: 10.1016/j.ncl.2018.04.001
2. McNeill KA. Epidemiology of brain tumors. Neurol Clin. (2016) 34:981–98. doi: 10.1016/j.ncl.2016.06.014
3. Butowski NA. Epidemiology and diagnosis of brain tumors. Continuum. (2015) 21:301–13. doi: 10.1212/01.CON.0000464471.50638.fa
4. D’Archivio M, Santangelo C, Scarcocchio B, Vare R, Fileu C, Masella R, et al. Modulatory effects of polyphenols on apoptosis induction: Relevance for cancer prevention. Int J Mol Sci. (2008) 9:213–28. doi: 10.3390/ijms9030213
5. Pouliquen D, Olivier C, Hervouet E, Pedelaborde F, Debien E, Le Cabellec MT, et al. Dietary prevention of malignant glioma aggressiveness, implications in oxidant stress and apoptosis. Int J Cancer. (2008) 123:288–95. doi: 10.1002/ijc.23513
6. Khoshyomn S, Nathan D, Manske GC, Osler TM, Penar PL. Synergistic effect of genistein and BCNU on growth inhibition and cytotoxicity of glioblastoma cells. J Neurooncol. (2002) 57:393–200. doi: 10.1023/a:1015765616484
7. Pawłowski E, Siczepanska J, Blasiak J. Pro- and antioxidant effects of vitamin c in cancer in correspondence to its dietary and pharmacological concentrations. Oxid Med Cell Longev. (2019) 2019:7286737. doi: 10.1155/2019/7286737
pregnancy and risk of childhood brain tumors. *Nutr. Cancer.* (2014) 66:800–9. doi: 10.1080/01635581.2014.916326

31. Bhatti DJ, Doody DR, Mckean-Cowdin R, Mueller BA. Neonatal vitamin D and childhood brain tumor risk. *Int J Cancer.* (2013) 133:2481–5. doi: 10.1002/ijc.28291

32. Greenop KR, Miller M, Bailey KD, de Klerk NH, Attila J, Kelleie SJ, et al. Childhood folate, B6, B12, and food group intake and the risk of childhood brain tumors: Results from an Australian case-control study. *Cancer Causes Control.* (2015) 26:871–9. doi: 10.1007/s10552-015-0562-z

33. Zigmunt V, Garrett A, Peng J, Seweryn M, Rempala GA, Harris R, et al. Association between prediagnostic serum 25-Hydroxyvitamin d concentration and glioma risk. *Nutr. Cancer.* (2015) 67:1120–30. doi: 10.1080/01635581.2015.1077357

34. Huang J, Weinstein SJ, Kitahara CM, Karoly ED, Sampson JN, Albanes D, et al. prospective study of serum metabolites and glioma risk. Oncotarget. (2017) 8:70366–77. doi: 10.18632/oncotarget.19705

35. Heydari M, Shayyafar M, Shariﬁ G, Sanei R, Sadeghi O, Esmaillzadeh A. The association between dietary total antioxidant capacity and glioma in adults. *Nutr. Cancer.* (2021) 73:1947–56. doi: 10.1080/01635581.2020.1817954

36. Yue Y, Creed HJ, Cote DJ, Stampley MJ, Wang M, Midtud O, et al. Pre-diagnostic circulating concentrations of fat-soluble vitamins and risk of glioma in three cohort studies. *Sci Rep.* (2021) 11:9198. doi: 10.1038/s41598-021-48845-0

37. Metodiewa D, Koska C. Reactive oxygen species and reactive nitrogen species: Relevance to cyto(neuro)toxic events and neurologic disorders. *Overy Neurotox.* (2000) 1:197–23. doi: 10.1080/1055-9965.2000.116922

38. Hung CF, Lu KH. Vitamin C inhibited DNA adduct formation and arylamine N-acetyltransferase activity and gene expression in rat glial tumor cells. *Neurochem Res.* (2000) 25:2167–72. doi: 10.1023/A:1011231470500

39. Hervouet E, Shaﬁlin O, Pouluquin D, Debiens E, Cartron PE, Menantaise J, et al. Antioxidants delay clinical signs and systemic effects of ENU induced brain tumors in rats. *Nutr. Cancer.* (2013) 65:886–94. doi: 10.1080/01635581.2013.789541

40. Yang GT, Chen TY, Chen C, Hung YT, Hseuh KC, Wu TK, et al. Antioxidant vitamins promote anticancer effects on low-concentration methotrexate-treated glioblastoma cells via enhancing the caspase-3 death pathway. *Food Sci Nutr.* (2019) 7:1308–16. doi: 10.1002/fsn3.2298

41. DeLorenzo GN, McCoy L, Tsai AL, Quesenberry CJ, Rice T, I’Yasova D, et al. Daily intake of antioxidants in relation to survival among adult patients diagnosed with malignant glioma. *BMC Cancer.* (2010) 10:215. doi: 10.1186/1471-2407-10-215

42. Ueno M, Inano H, Onoda M, Murase H, Ikota N, Kagoya TV, et al. Modiﬁcation of mortality and tumorigenicity by tocopherol-monoglutriole (TMG) administered after X irradiation in mice and rats. *Radiat Res.* (2009) 172:519–24. doi: 10.1662/RR1695.1

43. Liu RZ Li S, Garcia E, Ghebrehiwot DD, Poon HY, Essaw IC, et al. Association between cytoplasmic CRABP2, altered retinoic acid signaling, and poor prognosis in glioblastoma. *Glia.* (2016) 64:963–76. doi: 10.1002/glia.22576

44. Aggarwal S, Subbarwal M, Kumar S, Sharma M. Brain tumor and role of beta-carotene, a-tocopherol, superoxide dismutase and glutathione peroxidase. *J Cancer Res Ther.* (2006) 2:24–7. doi: 10.4103/0973-1482.131577

45. Wang CJ, Lin JK. Inhibitory effects of carotenoids and retinoids on the in vitro growth of rat C6 glioma cells. *Proc Natl Sci Counc Repub China B.* (1989) 13:176–83.

46. Terry MB, Howe G, Bogda AM, Zhang FF, Ahlbom A, Choi W, et al. An international case-control study of adult diet and brain tumor risk: a histology-specific analysis by food group. *Ann Epidemiol.* (2009) 19:161– 71. doi: 10.1016/j.annepidem.2008.12.010

47. Sirachainan N, Wongruangsi K, Kajnehucham S, Pakakasama S, Vuudthibhan A, Nuchprayoon I, et al. Folate pathway genetic polymorphisms and susceptibility of central nervous system tumors in Thai children. *Cancer Detect Prev.* (2008) 32:72–8. doi: 10.1016/j.cdp.2008.02.004

48. Liu H, Sun Q, Zhang M, Zhang Z, Fan X, Yuan H, et al. Differential expression of folate receptor 1 in medulloblastoma and the correlation with clinicopathological characters and target therapeutic potential. *Oncotarget.* (2017) 8:23048–60. doi: 10.18632/oncotarget.15480

49. Guo J, Schlich M, Cryan JF, O’Driscoll CM. Targeted drug delivery via folate receptors for the treatment of brain cancer: Can the promise be delivered? *J Pharmacol Sci.* (2017) 106:3413–20. doi: 10.1007/s13188-017-08009

50. Hervouet E, Debiens E, Campion L, Charbord I, Manenteaui J, Valentine FM, et al. Folate supplementation limits the aggressiveness of glioma via the remethylation of DNA repeats element and genes governing apoptosis and proliferation. *Clin Cancer Res.* (2009) 15:3519–29. doi: 10.1158/1078-0432.CCR-08-2062

51. Okada M, Suzuki S, Togashi K, Sugai A, Yamamoto M, Kitakana C. Targeting folate metabolism is selectively cytotoxic to glioma stem cells and
effectively cooperates with differentiation therapy to eliminate Tumor-Initiating cells in glioma xenografts. *Int J Mol Sci.* (2021) 22:1633. doi: 10.3390/ijms222111633

52. Lo CS, Kiang KM, Leung GK. Anti-tumor effects of vitamin D in glioblastoma: Mechanism and therapeutic implications. *Lab Invest.* (2022) 102:118–25. doi: 10.1038/s41374-021-00673-8

53. Baudet C, Perret E, Delpech B, Kaghad M, Brachet P, Wion D, et al. Differentially expressed genes in C69 glioma cells during vitamin D-induced cell death program. *Cell Death Differ.* (1998) 5:116–25. doi: 10.1038/sj.cdd.4400327

54. Said AK, Essien EE, Abbas M, Yu X, Xie W, Sun J, et al. Association between dietary nitrate, nitrite intake, and site-specific cancer risk: a systematic review and meta-analysis. *Nutrients.* (2022) 14:666. doi: 10.3390/nu14030666

55. Essien EE, Said AK, Cote A, Mohamed KS, Baig M, Habib M, et al. Drinking-water nitrate and cancer risk: a systematic review and meta-analysis. *Arch Environ Occup Health.* (2022) 77:51–67. doi: 10.1080/19338244.2020.1842313